Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Comprehensive target engagement by EZH2 inhibitor CPI-0209 allows for preferential targeting of ARID1A mutant urothelial carcinoma

ABSTRACT: Comprehensive target engagement by EZH2 inhibitor CPI-0209 allows for preferential targeting of ARID1A mutant urothelial carcinoma

PROVIDER: PRJNA736424 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Study of CPI-0209 in patients with advanced tumors.

Project description:Advanced bladder cancer remains a difficult cancer to treat, and for the majority of patients, current standard treatments ultimately prove ineffective. These tumors frequently harbor mutations in the BAF complex subunit ARID1A, which has been reported to confer sensitivity to EZH2 inhibition in several tumor types. Here we describe the generation of CPI-0209, a best-in-class, orally available EZH2 inhibitor. We show that mutant bladder cancer lines harboring ARID1A loss of function (LOF) mutations are preferentially sensitive to inhibition of EZH2. Treatment with CPI-0209 not only elicits a significant monotherapeutic response in ARID1A mutant models, it also outperforms cisplatin and improves response in chemo-resistant models. These findings shine light on new therapeutic opportunities for patients with advanced urothelial carcinoma.

2024-06-26 | GSE176490 | GEO

Epigenomic profile of bladder cancer cell line HT1376 treated with CPI-0209

2024-06-26 | GSE176486 | GEO

Transcriptomic change of bladder cancer cell lines treated with CPI-0209 [2]

2024-06-26 | GSE176362 | GEO

Transcriptomic change of ARDI1A mutant bladder cancer cell line treated with CPI-0209 or induced ARID1A expression

2024-06-26 | GSE176358 | GEO

Epigenomic change of ARDI1A mutant bladder cancer cell line treated with CPI-0209 or induced ARID1A expression

2024-06-26 | GSE176477 | GEO

Study of CPI-0209 in patients with advanced tumors.

Project description:Study of CPI-0209 in patients with advanced tumors.

| PRJNA736432 | ENA